<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569476</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111_GA101_Study_001</org_study_id>
    <nct_id>NCT02569476</nct_id>
  </id_info>
  <brief_title>BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies</brief_title>
  <official_title>A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with
      obinutuzumab in subjects with B-cell lymphoid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From first dose to withhin 28 days of last dose of BGB-3111</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity time (AUC∞)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2)</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BTK inhibition activity of BGB-3111 by measurement of free BTK</measure>
    <time_frame>the first 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every 12 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>B-cell Lymphoid Malignancies</condition>
  <arm_group>
    <arm_group_label>BGB-3111 and obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose-escalation part, the dose levels and regimens will be evaluated. In the indication-specific expansion cohorts, patients will be assigned to different cohorts based on histology type.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111 and Obinutuzumab</intervention_name>
    <arm_group_label>BGB-3111 and obinutuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥18 years, able and willing to provide written informed consent and to comply
             with the study protocol.

          -  Laboratory parameters as specified below:

               -  Hematologic: Platelet count &gt;40x10^9/L (may be post-transfusion); absolute
                  neutrophil count &gt;1.0x10^9/L (growth factor use is allowed to bring pre-treatment
                  neutrophils to &gt;1.0x10^9 cells/L if marrow infiltration is involved).

               -  Hepatic: Total bilirubin &lt;3 x upper limit normal (ULN); and aspartate
                  aminotransferase (AST) and alanine transaminase (ALT) ≤3xULN.

               -  Renal: Creatinine clearance ≥50 mL/min (as estimated by the Cockcroft Gault
                  equation or as measured by nuclear medicine scan or 24 hour urine collection);
                  subjects requiring hemodialysis will be excluded.

          -  Anticipated survival of at least 6 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          -  Female subjects of childbearing potential and non-sterile males must agree to practice
             at least one of the following methods of birth control with partner(s) throughout the
             study and for ≥3 months after discontinuing BGB-3111 or ≥18 months following
             obinutuzumab treatment, whichever is longer: total abstinence from sexual intercourse,
             double barrier contraception, intra uterine device (IUD) or hormonal contraceptive
             initiated at least 3 months prior to first administration of study drug.

          -  Male subjects must not donate sperm from first study drug administration, until 3
             months after BGB-3111 discontinuation or 18 months following obinutuzumab treatment,
             whichever is longer.

        Exclusion Criteria:

          -  Known central nervous system lymphoma or leukemia.

          -  Known prolymphocytic leukemia or history of, or currently suspected, Richter's
             syndrome.

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.

          -  History of significant cardiovascular disease.

          -  Severe or debilitating pulmonary disease.

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy.

          -  Prior BTK inhibitor treatment.

          -  Using medications which are strong cytochrome P450 (CYP) 3A inhibitors and strong
             CYP3A inducers.

          -  Vaccination with a live vaccine within 28 days of the initiation of treatment.

          -  Allogeneic stem cell transplantation within 6 months, or has active graft versus host
             disease (GvHD) requiring ongoing immunosuppression.

          -  Receipt of the following treatment prior to first administration of BGB 3111,
             corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or
             radiotherapy within 3 weeks, monoclonal antibody within 4 weeks.

          -  Participate in any investigational drug study within 28 days of study entry, or not
             recovered from non-hematologic toxicity of any prior chemotherapy up to ≤ Grade 1
             (except for alopecia).

          -  History of other active malignancies within 2 years of study entry.

          -  Major surgery in the past 4 weeks.

          -  Active symptomatic fungal, bacterial and/or viral infection including evidence of
             infection with human immunodeficiency virus (HIV), human T cell lymphotropic virus
             (HTLV 1) seropositive status.

          -  Inability to comply with the study procedures.

          -  Pregnant or nursing women.

          -  Any illness or condition that in the opinion of the investigator may affect the safety
             of treatment or evaluation of any study's endpoints.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>William Novonty, MD</last_name>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brisbane Clinic for Lymphoma, Myeloma and Leukaemia</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Geelong</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Frances Xavier Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>October 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BGB-3111</keyword>
  <keyword>Obinutuzumab</keyword>
  <keyword>B-cell</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Therapeutic uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

